## P Willem Kamphuisen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5393140/publications.pdf

Version: 2024-02-01

28 papers 1,181 citations

471061 17 h-index 26 g-index

28 all docs

28 docs citations

times ranked

28

1857 citing authors

#	Article	IF	CITATIONS
1	Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Advances, 2020, 4, 5215-5225.	2.5	35
2	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood, 2020, 136, 1433-1441.	0.6	106
3	Anticoagulant activity of edoxaban in patients with cirrhosis. Blood, 2020, 136, 1561-1564.	0.6	14
4	Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis. Thrombosis and Haemostasis, 2019, 119, 246-253.	1.8	52
5	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE. Thrombosis and Haemostasis, 2019, 119, 675-684.	1.8	9
6	Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism—Analysis of the CATCH Study. Thrombosis and Haemostasis, 2018, 118, 914-921.	1.8	37
7	European guidelines on perioperative venous thromboembolism prophylaxis. European Journal of Anaesthesiology, 2018, 35, 139-141.	0.7	16
8	Management and outcome of major bleeding in patients receiving vitamin K antagonists for venous thromboembolism. Thrombosis Research, 2018, 171, 74-80.	0.8	11
9	Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability?. Thrombosis and Haemostasis, 2017, 117, 1622-1629.	1.8	17
10	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. Lancet Haematology, the, 2016, 3, e267-e275.	2.2	55
11	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. European Respiratory Journal, 2016, 48, 780-786.	3.1	199
12	Letter to the Editor. Journal of Intensive Care Medicine, 2016, 31, 70-71.	1.3	0
13	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. JAMA Internal Medicine, 2015, 175, 1474.	2.6	180
14	Evaluation of coagulation activation after Rhinovirus infection in patients with asthma and healthy control subjects: an observational study. Respiratory Research, 2014, 15, 14.	1.4	21
15	Dabigatran-related coagulopathy: when can we assume the effect has "worn off�. American Journal of Emergency Medicine, 2014, 32, 1433-1434.	0.7	1
16	A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 959-965.	1.8	16
17	Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials. PLoS Medicine, 2012, 9, e1001310.	3.9	78
18	Coagulation activation and microparticle-associated coagulant activity in cancer patients. Thrombosis and Haemostasis, 2012, 108, 160-165.	1.8	90

#	Article	IF	CITATION
19	Cardiovascular risk assessment in haemophilia patients. Thrombosis and Haemostasis, 2011, 105, 274-278.	1.8	71
20	Nonâ€steroidal antiâ€inflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiology and Drug Safety, 2011, 20, 635-642.	0.9	19
21	Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Thrombosis and Haemostasis, 2010, 104, 831-836.	1.8	41
22	Comparison of 4- and 64-slice CT scanning in the diagnosis of pulmonary embolism. Thrombosis and Haemostasis, 2010, 103, 242-246.	1.8	30
23	Statin Treatment Reduces the Incidence of Recurrent Pulmonary Embolism: a Population Based Case-Control Study. Blood, 2010, 116, 808-808.	0.6	0
24	Systolic Heart Failure: A Prothrombotic State. Seminars in Thrombosis and Hemostasis, 2009, 35, 497-504.	1.5	26
25	Management Strategies for Optimal Control of Anticoagulation in Patients with Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2009, 35, 560-567.	1.5	17
26	Hemostatic Abnormalities and Arterial Thrombosis. Seminars in Thrombosis and Hemostasis, 2009, 35, 449-450.	1.5	2
27	Thrombolysis for Pulmonary Embolism and Venous Thrombosis: Is It Worthwhile?. Seminars in Thrombosis and Hemostasis, 2007, 33, 821-828.	1.5	15
28	Venous Thrombosis at Unusual Sites and the Role of Thrombophilia. Seminars in Thrombosis and Hemostasis. 2007. 33, 582-587.	1.5	23